Nuveen
NRIX icon

Nuveen’s Nurix Therapeutics NRIX Stock Holding History

Nuveen’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$20M Buy
825,833
+13,232
+2% +$225K ﹤0.01% 1266
2026
Q1 		$12.6M Buy
812,601
+28,192
+4% +$467K ﹤0.01% 1421
2025
Q4 		$14.9M Buy
784,409
+632,349
+416% +$9.08M ﹤0.01% 1316
2025
Q3 		$1.41M Hold
152,060
– – ﹤0.01% 2456
2025
Q2 		$1.73M Sell
152,060
-17,085
-10% -$185K ﹤0.01% 2369
2025
Q1 		$2.01M Sell
169,145
-240,492
-59% -$4.02M ﹤0.01% 2336
2024
Q4 		$7.72M Sell
409,637
-263,917
-39% -$6.05M ﹤0.01% 1741
2024
Q3 		$15.1M Sell
673,554
-307,613
-31% -$6.97M ﹤0.01% 1365
2024
Q2 		$20.5M Buy
981,167
+562,344
+134% +$8.76M 0.01% 1111
2024
Q1 		$6.16M Sell
418,823
-115,042
-22% -$1.24M ﹤0.01% 1867
2023
Q4 		$5.51M Sell
533,865
-129,395
-20% -$887K ﹤0.01% 1923
2023
Q3 		$5.21M Sell
663,260
-4,157
-0.6% -$38K ﹤0.01% 1847
2023
Q2 		$6.67M Sell
667,417
-2,556
-0.4% -$26.1K ﹤0.01% 1757
2023
Q1 		$5.95M Sell
669,973
-20,392
-3% -$213K ﹤0.01% 1791
2022
Q4 		$7.58M Buy
690,365
+137,709
+25% +$1.66M ﹤0.01% 1671
2022
Q3 		$7.2M Buy
552,656
+228,071
+70% +$3.61M ﹤0.01% 1683
2022
Q2 		$4.11M Buy
324,585
+219,194
+208% +$2.48M ﹤0.01% 2073
2022
Q1 		$1.44M Buy
105,391
+10,614
+11% +$188K ﹤0.01% 2664
2021
Q4 		$2.49M Sell
94,777
-7,082
-7% -$215K ﹤0.01% 2464
2021
Q3 		$3.67M Sell
101,859
-46,900
-32% -$1.45M ﹤0.01% 2374
2021
Q2 		$3.95M Buy
148,759
+8,702
+6% +$255K ﹤0.01% 2360
2021
Q1 		$4.35M Buy
140,057
+41,216
+42% +$1.56M ﹤0.01% 2229
2020
Q4 		$3.25M Buy
98,841
+31,991
+48% +$1.06M ﹤0.01% 2272
2020
Q3 		$2.33M Buy
+66,850
New +$1.68M ﹤0.01% 2301

Other funds holding NRIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Nuveen's NRIX Position: Q2 2026 in Review

Nuveen increased its Nurix Therapeutics (NRIX) stake by 1.6% in Q2 2026, buying an estimated $225K and bringing the position to 825,833 shares worth $20M. The position accounts for ﹤0.01% of the portfolio, ranked #1266.

Nuveen first reported a position in NRIX in Q3 2020 and has held it in 24 quarters since. The position peaked at $20.5M in Q2 2024. 212 funds tracked by Wall St. Rank hold NRIX as of Q2 2026.

  • Nuveen held 825,833 shares of Nurix Therapeutics worth $20M as of Q2 2026.
  • Nuveen bought 13,232 Nurix Therapeutics shares in Q2 2026, an estimated $225K.
  • Nurix Therapeutics made up ﹤0.01% of Nuveen's portfolio in Q2 2026, its #1266 holding.
  • Nuveen first reported a position in Nurix Therapeutics in Q3 2020 and has held it in 24 quarters since.
  • Nuveen's Nurix Therapeutics position peaked at $20.5M in Q2 2024.
  • 212 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.